Back to Search Start Over

High rates of 30-day mortality in patients with cirrhosis and COVID-19

Authors :
Iavarone, M
D'Ambrosio, R
Soria, A
Triolo, M
Pugliese, N
Del Poggio, P
Perricone, G
Massironi, S
Spinetti, A
Buscarini, E
Viganò, M
Carriero, C
Fagiuoli, S
Aghemo, A
Belli, L
Lucà, M
Pedaci, M
Rimondi, A
Rumi, M
Invernizzi, P
Bonfanti, P
Lampertico, P
Iavarone, Massimo
D'Ambrosio, Roberta
Soria, Alessandro
Triolo, Michela
Pugliese, Nicola
Del Poggio, Paolo
Perricone, Giovanni
Massironi, Sara
Spinetti, Angiola
Buscarini, Elisabetta
Viganò, Mauro
Carriero, Canio
Fagiuoli, Stefano
Aghemo, Alessio
Belli, Luca S
Lucà, Martina
Pedaci, Marianna
Rimondi, Alessandro
Rumi, Maria Grazia
Invernizzi, Pietro
Bonfanti, Paolo
Lampertico, Pietro
Iavarone, M
D'Ambrosio, R
Soria, A
Triolo, M
Pugliese, N
Del Poggio, P
Perricone, G
Massironi, S
Spinetti, A
Buscarini, E
Viganò, M
Carriero, C
Fagiuoli, S
Aghemo, A
Belli, L
Lucà, M
Pedaci, M
Rimondi, A
Rumi, M
Invernizzi, P
Bonfanti, P
Lampertico, P
Iavarone, Massimo
D'Ambrosio, Roberta
Soria, Alessandro
Triolo, Michela
Pugliese, Nicola
Del Poggio, Paolo
Perricone, Giovanni
Massironi, Sara
Spinetti, Angiola
Buscarini, Elisabetta
Viganò, Mauro
Carriero, Canio
Fagiuoli, Stefano
Aghemo, Alessio
Belli, Luca S
Lucà, Martina
Pedaci, Marianna
Rimondi, Alessandro
Rumi, Maria Grazia
Invernizzi, Pietro
Bonfanti, Paolo
Lampertico, Pietro
Publication Year :
2020

Abstract

Background & Aims: Coronavirus disease 2019 (COVID-19) poses a major health threat to healthy individuals and those with comorbidities, but its impact on patients with cirrhosis is currently unknown. Herein, we aimed to evaluate the impact of COVID-19 on the clinical outcome of patients with cirrhosis. Methods: In this multicentre retrospective study, patients with cirrhosis and a confirmed severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection were enrolled between 1st and 31th March 2020. Clinical and biochemical data at diagnosis of COVID-19 and at the last outpatient visit were obtained through review of medical records. Results: Fifty patients with cirrhosis and confirmed SARS-CoV-2 infection were enrolled (age 67 years, 70% men, 38% virus-related, 52% previously compensated cirrhosis). At diagnosis, 64% of patients presented fever, 42% shortness of breath/polypnea, 22% encephalopathy, 96% needed hospitalization or a prolonged stay if already in hospital. Respiratory support was necessary in 71%, 52% received antivirals, 80% heparin. Serum albumin significantly decreased, while bilirubin, creatinine and prothrombin time significantly increased at COVID-19 diagnosis compared to last available data. The proportion of patients with a model for end-stage liver disease (MELD) score ≥15 increased from 13% to 26% (p = 0.037), acute-on-chronic liver failure and de novo acute liver injury occurred in 14 (28%) and 10 patients, respectively. Seventeen patients died after a median of 10 (4–13) days from COVID-19 diagnosis, with a 30-day-mortality rate of 34%. The severity of lung and liver (according to CLIF-C, CLIF-OF and MELD scores) diseases independently predicted mortality. In patients with cirrhosis, mortality was significantly higher in those with COVID-19 than in those hospitalized for bacterial infections. Conclusion: COVID-19 is associated with liver function deterioration and elevated mortality in patients with cirrhosis. Lay summary: Coronavirus

Details

Database :
OAIster
Notes :
English
Publication Type :
Electronic Resource
Accession number :
edsoai.on1308934395
Document Type :
Electronic Resource